Figure 3. mCuMVTT-RBM promotes IgA production
and IgG responses are dominated with IgG2a subclass
A, RBD-specific IgG titer for the groups vaccinated with
CuMVTT as a control and mCuMVTT-RBM
vaccine candidate on days 7, 14, 21 and 42 measured by ELISA by ELISA
OD450. B, Log OD50 of RBD-specific IgG
titer for the groups vaccinated with CuMVTT as a control
and mCuMVTT-RBM vaccine candidate on days 7, 14, 21 and
42 (Data from A). C, Spike-specific IgG titer for the groups vaccinated
with CuMVTT as a control and mCuMVTT-RBM
vaccine candidate on days 7, 14, 21 and 42 measured by ELISA
OD450. D, Log OD50 of spike-specific IgG
titer for the groups vaccinated with CuMVTT as a control
and mCuMVTT-RBM vaccine candidate on days 7, 14, 21 and
42 (Data from C). CuMVTT n=5 and
mCuMVTT-RBM n=10 . E, RBD-specific IgA titer for
the groups vaccinated with CuMVTT as a control and
mCuMVTT-RBM vaccine candidate using D0/D14 and D0/D28
regimens, measured by ELISA OD450. F, Log
OD50 of RBD-specific IgA titer for the groups vaccinated
with CuMVTT as a control and mCuMVTT-RBM
vaccine candidate using D0/D14 and D0/D28 regimens, sera of day 35 was
used. CuMVTT n=5 and mCuMVTT-RBMn=5. Statistical analysis (mean ± SEM) using Student’s
t-test . One representative of 3 similar experiments is shown. The value
of p<0.05 was considered statistically significant
(*p <0.01, **p <0.001,
***p <0.0001).